Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
637
datasets available to search
ShareScore release 0.9.0
Dataset results
637 results for “thyroid cancer”
Improving The Diagnosis of Thyroid Cancer by Machine Learning and Clinical Data
<p>This repository contains the dataset used in the paper "Improving The Diagnosis of Thyroid Cancer by Machine Learning and Clinical Data" published in <strong>Scientific Reports</strong>. Please check our <a href="https://www.nature.com/articles/s41598-022-15342-z">formal publication</a> for the full details. The dataset contains 1232 nodules from 724 patients. Each row represents one nodule and each column represents one variable that describes the characteristics of the patient or nodule. The meaning of each variable is summarized below.</p> <ul> <li>id: the unique identity of the patient who carries the nodule</li> <li>age: the age of the patient</li> <li>FT3: triiodothyronine test result</li> <li>FT4: thyroxine test result</li> <li>TSH: thyroid-stimulating hormone test result</li> <li>TPO: thyroid peroxidase antibody test result</li> <li>TGAb: thyroglobulin antibodies test result</li> <li>site: the nodule location, 0: right, 1: left, 2: isthmus</li> <li>echo_pattern: thyroid echogenicity, 0: even, 1: uneven</li> <li>multifocality: if multiple nodules exist in one location, 0: no, 1: yes</li> <li>size: the nodule size in cm</li> <li>shape: the nodule shape, 0: regular, 1: irregular</li> <li>margin: the clarity of nodule margin, 0: clear; 1: unclear</li> <li>calcification: the nodule calcification, 0: absent, 1: present</li> <li>echo_strength: the nodule echogenicity, 0: none, 1: isoechoic, 2: medium-echogenic, 3: hyperechogenic, 4: hypoechogenic</li> <li>blood_flow: the nodule blood flow, 0: normal, 1: enriched</li> <li>composition: the nodule composition, 0: cystic, 1: mixed, 2: solid</li> <li>multilateral: if nodules occur in more than one location, 0: no, 1: yes</li> <li>mal: the nodule malignancy, 0: benign, 1: malignant</li> </ul>
Selpercatinib treatment of RET mutated thyroid cancers is associated with gastrointestinal adverse effects
<p><strong>Background:</strong></p> <p>Metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAI-R DTC) have poor prognosis and limited treatment options. Selpercatinib (LOXO-292), a selective kinase inhibitor targeting the <em>RET</em> gene, has shown a 69-79% objective responses have been observed in this cohort (1) with benefits in other tumours harbouring the same oncogenic driver (2). Published reports describe only 17% of patients experiencing gastrointestinal Adverse effects (AE) which is in contrast to our local experience. Here we characterise the AE and correlate with radiological and histopathological findings. </p> <p><strong>Methods:</strong></p> <p>Sequential patients enrolled in LIBRETTO-001 at Royal North Shore Hospital, Sydney with available imaging (n=22) were recruited. Patients had regular visits with AE documented and CT scans 3 monthly. CT at screening, at time of gastrointestinal AE and at most recent follow up were reviewed and scored. Endoscopic examination was performed in five patients.</p> <p><strong>Results:</strong></p> <p>Of 22 patients in this cohort, the majority had somatic <em>RET </em>alterations (n=18), most commonly <em>p.Met918Thr</em> (n=14). Ten patients (50%) developed gastrointestinal adverse effects. Dose reduction was required in 8 of the 10 patients, but none discontinued therapy. The majority had stable disease (n=17). Gastric and small bowel oedema was evident in symptomatic patients after a median time of 67 weeks’ treatment. Histological correlation in five patients revealed mucosal oedema correlating with radiological evidence of congestion and oedema.</p> <p><strong>Discussion: </strong></p> <p>Gastrointestinal AEs with selpercatinib may be more common than previously described. Most are self-limiting but often require dose adjustments. Histological evidence of mucosal oedema observed in conjunction with the radiological findings of congestion and wall thickening suggest that bowel wall oedema is a predominant mechanism of abdominal pain in these patients.</p>
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
ClinicalTrials.gov study NCT04462471. IPD Sharing: YES. Countries: 1. Publications: 1.
The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer
ClinicalTrials.gov study NCT05132478. IPD Sharing: YES. Countries: 1. Publications: 0.
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
ClinicalTrials.gov study NCT00537095. IPD Sharing: YES. Countries: 7. Publications: 1.
Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant.
<p>Supplementary Data for the manuscript: Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant. Nikita Pozdeyev, MD, PhD (ORCiD ID: 0000-0001-8574-1972), Manjiri Dighe, MD, Martin Barrio, MD, MS, Christopher Raeburn, MD, Harry Smith, MS, Matthew Fisher, MS, Sameer Chavan, MS, Nicholas Rafaels, MS, Jonathan A. Shortt, PhD, Meng Lin, PhD, Michael G. Leu, MD, Toshimasa Clark, MD, Carrie Marshall, MD, Bryan R. Haugen, MD, Devika Subramanian, PhD, Regeneron Genetics Center, Kristy Crooks, PhD, Christopher Gignoux, PhD, Trevor Cohen, MBChB, PhD, FACMI</p>
Spatial transcriptomics images for papillary and anaplastic thyroid cancer IRIBHM dataset
<p>This dataset includes the image files for spatial transcriptomics data associated with the publication "Idiosyncratic and generic single nuclei and spatial transcriptional patterns in papillary and anaplastic thyroid cancers".</p>
Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
ClinicalTrials.gov study NCT00181168. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
ClinicalTrials.gov study NCT03037385. IPD Sharing: NO. Countries: 13. Publications: 8.
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
ClinicalTrials.gov study NCT04211337. IPD Sharing: YES. Countries: 20. Publications: 3.
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
ClinicalTrials.gov study NCT00134043. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
ClinicalTrials.gov study NCT00970359. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of E7080 in Subjects With Advanced Thyroid Cancer
ClinicalTrials.gov study NCT01728623. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy
ClinicalTrials.gov study NCT02702388. IPD Sharing: Not stated. Countries: 16. Publications: 2.
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
ClinicalTrials.gov study NCT01856920. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
ClinicalTrials.gov study NCT00251316. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
ClinicalTrials.gov study NCT02152137. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
ClinicalTrials.gov study NCT01811212. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
ClinicalTrials.gov study NCT00984282. IPD Sharing: Not stated. Countries: 18. Publications: 5.
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
ClinicalTrials.gov study NCT02657369. IPD Sharing: YES. Countries: 5. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.